Reduced Oligodendrocyte-specific Cytotoxicity and Ofatumumab Treatment

Inclusion Criteria: RR-MS patients only: This investigator-initiated study/trial (IIT) will be carried out secondary to the discussion of treatment with Ofatumumab and thus our study will not influence or impact the determination of the suitability for candidates to commence therapy with Ofatumumab. This decision will be made by the patient's physician as part of the patient's standard care, and will occur independently of this study. Patients to be enrolled in this longitudinal study will only be asked if they would like to take part in this IIT if their clinician independently chooses Ofatumumab as a treatment option: * Patients must qualify to receive treatment with Ofatumumab (Kesimpta), according to the Multiple Sclerosis Comprehensive Care Center at USC Keck School of Medicine or LAC+USC Medical Center and meet the inclusion criteria defined in, and aligned with, the US Kesimpta (Ofatumumab) Prescribing Information. * Patients must have clinically definite Multiple Sclerosis as defined by the revised McDonald criteria of the relapsing-remitting form with an Expanded Disability Status Scale (EDSS) score of 0 to 5.5. * Patients must be treatment naive to Ofatumumab (Kesimpta) * Patients must have the ability to understand and sign this study-specific IRB-approved informed consent form. * Patients must be willing to donate \~80ml of blood each for M00 and M06 that will be used for testing the specific aims described in this proposal. * Patients must have a lymphocyte co…